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Abstract
Background: Treatment options for at-home management of cluster seizures (CS) and
status epilepticus (SE) are limited. The pharmacokinetics of levetiracetam (LEV) after
rectal administration in both healthy and epileptic dogs has been investigated recently.
Hypothesis/Objectives: To investigate the clinical efficacy of rectally administered
LEV in preventing additional seizures in dogs presented for CS and SE. We hypothe-
sized that rectal administration of LEV in addition to a standard treatment protocol
would provide better control of seizure activity as compared with the standard treat-
ment protocol alone.
Animals: Fifty-seven client-owned dogs with CS or SE.
Methods: Prospective open-label clinical trial. Patients included in the study were
assigned to receive either a standard treatment protocol comprising IV/rectal diaze-
pam and IV phenobarbital q8h (control group) or a standard treatment protocol in
association with a single dose of 40 mg/kg LEV rectally (rectal LEV group). Dogs that
experienced no additional seizures were defined as responders, whereas those that
showed additional seizure activity were classified as nonresponders.
Results: Twenty-one dogs were assigned to the rectal LEV group, and 36 to control
group. Given the small number of cases of SE, statistical analysis was performed only
on patients with CS. The response rate was 94% in the rectal LEV group and 48% in
the control group (P < .001).
Conclusions and Clinical Importance: Rectally administered LEV combined with a
standard treatment protocol provided good control of seizure activity in patients with
CS. The validity of these results should be confirmed in a double-blinded, placebo-
controlled clinical trial.
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1 | INTRODUCTION
Medical literature provides evidence for progressive loss of efficacy of
benzodiazepines during prolonged seizure activity because of a func-
tional alteration of gamma aminobutyric acid-A receptors that are
internalized into the cells.1 This limitation has prompted investigation
of other treatment options for the emergency management of these
neurological conditions. Furthermore, in both human and veterinary
medicine, treatment guidelines for cluster seizures (CS) and status
epilepticus (SE) must balance the need for seizure control with the
risk of dangerous adverse effects (eg, cardiorespiratory depression)
associated with antiepileptic medication (AEM) administration.1,2 To
enhance the anticonvulsant action of AEMs and decrease the occur-
rence of adverse effects, the concept of early polytherapy recently
has been introduced in human medicine.3 Although the literature on
early combined polytherapy is still limited, it is hypothesized that
AEMs with different molecular mechanisms of action can be com-
bined together so as to enhance their anticonvulsant properties.4
Because of its different mechanism of action, its favorable phar-
macokinetics, and favorable safety profile, levetiracetam (LEV) has
been investigated as a candidate for early combined polytherapy in
human medicine. In particular, 2 experimental studies on mice and
human patients have provided evidence of synergy between LEV and
diazepam.5,6 Levetiracetam use also has gradually increased in recent
years in veterinary medicine as long-term monotherapy or pulse treat-
ment given IV or PO in CS patients.7,8 The latter treatment strategy
has been proposed to avoid the induction of LEV tolerance as
reported in both mice and dogs.9,10
The PO route can be easily employed by owners at home. How-
ever, the postictal phase in epileptic patients can impair swallowing
ability, preventing use of the PO route because of aspiration risk, thus
delaying the initiation of treatment. For this reason, we evaluated
another route of administration of LEV in epileptic patients.
The pharmacokinetics of LEV after rectal administration in both
healthy and epileptic dogs recently has been investigated. These stud-
ies indicated that administration of 40 mg/kg per rectum achieved the
minimum target concentration of 5 μg/mL 10 and 30 minutes after
the administration in healthy and affected dogs, respectively.11,12
Our aim was to investigate the clinical efficacy of rectally adminis-
tered LEV in preventing additional seizures when administered to
dogs presented for CS and SE. We hypothesized that administration
of LEV rectally in addition to a standard treatment protocol would
provide better control of seizure activity as compared with the stan-
dard treatment protocol alone.
2 | MATERIALS AND METHODS
The study was approved by the Bioethics Committee of the Univer-
sity of Turin (protocol #9834, dated February 25, 2016). Written
informed consent was obtained from the dog owners before enroll-
ment in this open-label clinical trial.
2.1 | Dogs
Dogs referred to the Veterinary Teaching Hospital (VTH) of the
Department of Veterinary Science, Turin, between September 2016
and May 2018 for CS or SE of any type were eligible for inclusion in
the study. No age, breed, or sex limitations were applied. If the dogs
were referred to the VTH for CS or SE multiple times during the study
period, only the first hospitalization was considered for the purpose
of the study. Status epilepticus and CS were defined according to the
definitions of the International Veterinary Epilepsy Task Force (IVETF)
consensus report.13
Minimum database blood tests, including CBC, serum biochemis-
try profile, serum electrolyte concentrations, blood ammonia concen-
tration, and preprandial and postprandial bile acid concentrations
were performed. All dogs underwent neurological examination by a
board-certified neurologist (A.D.) or a neurology resident (G.C.) under
the supervision of the board-certified neurologist. Dogs were excluded
if already under treatment with LEV for long-term seizure control or if
further diagnostic tests indicated reactive seizures.
A diagnosis of idiopathic epilepsy was made according to the
IVETF consensus report,14 whereas a diagnosis of structural epilepsy
was suspected when reactive causes of seizures were excluded,
along with signalment, history, and an abnormal interictal neurological
examination. Magnetic resonance imaging results, cerebrospinal fluid
analysis results or both were included if available but were not
required for the diagnosis of structural epilepsy.
Eight dogs included in the present study had been enrolled in a
previous study evaluating the pharmacokinetics of LEV administered
per rectum in dogs with CS and SE.12
2.2 | Study design
At the time of presentation to the VTH, a standard care protocol
comprising rectal/IV diazepam (at a dosage of 1-2 mg/kg if the
patient was seizuring at presentation) followed by IV phenobarbi-
tal (PB; 4-5 mg/kg q8h) was administered to each dog. After admin-
istration of these medications, the patients were selected to receive
either a single dose of rectal LEV at a dosage of 40 mg/kg in
association with PB q8h (rectal LEV group) or no other medica-
tions except for PB q8h (control group). No proper randomization
of patients between the 2 study groups was performed because
the dog owner, through written informed consent, made the final
decision for assigning the dog to the rectal LEV group or control
group.
The LEV suspension employed was created and administered as
previously reported.12 The dogs were monitored for additional sei-
zures for the first 24 hours after admission and until discharge. Dogs
that experienced no additional seizures in the first 24 hours were
defined as responders, whereas those that showed additional seizure
activity and therefore required other AEMs in the first 24 hours were
classified as nonresponders.
CAGNOTTI ET AL. 1715
2.3 | Statistical analysis
Statistical analysis was performed using commercially available soft-
ware (R 3.5.2—R Core Team, 2018). Data were analyzed for normality
using the Shapiro-Wilk test and were found to be nonparametric.
Numerical data (age and body weight) were tested using the Wilcoxon
rank sum test; categorical data (sex, reason for presentation, and sei-
zure etiology) were tested using the test for equality of proportions or
Chi-square test, where appropriate. A comparison between the number
of responders versus nonresponders between the 2 groups was carried
out using Fisher's 2-tailed exact test. In addition, a comparison between
the number of responders versus nonresponders in relation to the etiol-
ogy (idiopathic versus suspected or confirmed structural epilepsy) of
seizure activity was performed using Fisher's 2-tailed exact test. Results
were considered statistically significant at a significance level of P < .05.
3 | RESULTS
Sixty-six dogs were referred because of CS and SE to the VTH
between September 2016 and May 2018. Nine of 66 patients were
excluded from the study. Four patients were excluded because further
investigations led to a diagnosis of reactive seizures, 4 because they
were already being treated with LEV for long-term seizure control,
and 1 patient because the episodes possibly related to seizure activity
were witnessed only by the owner and no proper evidence of epilep-
tic seizures could be obtained, respectively.
In total, 57 patients were included in the study: 21 dogs were
assigned to the rectal LEV group and received 40 mg/kg of LEV per
rectum in addition to the standard protocol, and 36 were assigned to
the control group and received only the standard care protocol.
Table 1 presents signalment and patient characteristics. There were
no statistically significant differences in median age, sex, body weight,
reason for presentation, and seizure etiology between the LEV and
the control group.
A diagnosis of idiopathic epilepsy (Tier I or II confidence level
using the IVETF consensus report) was present in 16 patients in the
control group (44%) and in 12 patients in the rectal LEV group (57%).
A structural etiology was suspected or confirmed in 20 patients (56%)
in the control group and in 9 (43%) in the rectal LEV group. Table 1
presents details on the definitive diagnoses.
Given the small number of patients admitted with SE in both
groups, statistical analysis was performed taking into consideration
only patients affected by CS. Fisher's 2-tailed exact test showed a sta-
tistically significant difference (P < .001) between the 2 groups: the
response rate was 94% (17/18) in the rectal LEV group and 48%
(15/31) in the control group.
Fisher's 2-tailed exact test showed no statistically significant dif-
ferences between the response rate of patients affected by idiopathic
and those with suspected or confirmed structural epilepsy (P = 1).
When the test was performed on each group separately, no statisti-
cally significant differences were found (rectal LEV group, P = .48;
control group, P = 1).
TABLE 1 Information on patients included in the study for each study group. No statistically significant differences were found between the
2 study groups in age, sex, body weight, reason for presentation, and seizure etiology. The smallest P value obtain was .08 (sex)
Rectal LEV group Control group
Breed Mixbreed (8/21), French Bulldog (3/21), Boxer (2/21),
Corso Dog (2/21), German Shepherd (2/21),
Bloodhound (1/21), Dachshund (1/21), Pyrenean
Mountain Dog (1/21), Argentine Mastiff (1/21)
Mixbreed (14/36), Border Collie (3/36), Pinscher (2/36),
Yorkshire Terrier (2/36), American Staffordshire (1/36),
Bernese Mountain Dog (1/36), Breton (1/36), Cavalier King
Charles Spaniel (1/36), Chihuahua (1/36), Dogue de Bordeaux
(1/36), English Bulldog (1/36), German Shepherd (1/36),
Golden Retriever (1/36), Labrador Retriever (1/36), Maltese
(1/36), Poodle (1/36), Pug (1/36), Siberian Husky (1/36),
Spitz (1/36)
Age Median 75 (range, 49-113 months) Median 68 (range, 31.5-93 months)
Sex 12 males (57%), 5 females (24%), 3 males neutered (14%),
1 female neutered (5%)
20 males (55%), 10 females (28%), 6 females neutered (17%)
Body weight Median 24 (range, 16-28.7 kg) Median 16 (range, 7.15-27.8 kg)
Epilepsy etiology 10 dogs Tier I idiopathic epilepsy,
2 dogs Tier II idiopathic epilepsy,
3 dogs intracranial neoplasia,
1 dog hemorrhagic stroke,
5 dogs suspected undefined structural epilepsy
9 dogs Tier I idiopathic epilepsy,
7 dogs Tier II idiopathic epilepsy,
2 dogs undefined degenerative disease,
2 dogs meningoencephalitis of unknown origin,
1 dog hydrocephalus,
1 dog intracranial neoplasia,
16 dogs suspected undefined structural epilepsy
Long-term AEMs PB (5/21), PB and KBr (3/21), Imepitoin (1/21), none
(12/21)
PB (10/36), PB and KBr (4/36), none (22/36)
Presentation Generalized SE (3/21), CS (18/21) Generalized SE (5/36), CS (31/36)
Abbreviations: CS, cluster seizures; KBr, Potassium Bromide; LEV, levetiracetam; PB, phenobarbital; SE, Status epilepticus; AEMs, antiepileptic medications.
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4 | DISCUSSION
Our study provides preliminary evidence for the efficacy of rectally
administered LEV when combined with a standard treatment protocol
in preventing the onset of additional epileptic seizures in dogs
with CS. Given the promising results of previous pharmacokinetics
studies,11,12 we evaluated the potential beneficial effect of rectally
administered LEV combined with other AEMs in controlling seizure
activity in dogs with CS. Our results show that dogs with CS treated
using rectally administered LEV in addition to a standard treatment
protocol consisting of diazepam and PB experienced substantially bet-
ter control of seizures as compared with a control group of patients
treated with AEMs using the standard treatment protocol alone.
These results suggest that rectal administration could represent a via-
ble alternative to PO administration of AEMs and therefore extend
treatment options for the at-home management of these neurological
emergencies before referral to a specialized veterinary clinic or
hospital.
The lack of a placebo-controlled group of patients is the main limi-
tation of our study. Of note, however, is that a reduction in placebo
exposure recently has been advocated in human medicine. The sud-
den unexpected death in epilepsy (SUDEP) rate has been reported to
be higher among placebo-treated participants of add-on treatment
epilepsy trials in human medicine, suggesting that adding effective
AEMs instead of placebo in epilepsy trials can decrease the risk of
death of epileptic patients.15
Death during or immediately after seizure activity has been docu-
mented in epileptic dogs as well, suggesting that the concept of SUDEP
also can be extended to veterinary patients.16 The add-on administra-
tion of AEMs to a standard antiepileptic regimen therefore seems a
valuable alternative to a placebo-controlled trial, even if the latter study
design still represents the gold standard for treatment investigations.
In our study, allocation to the 2 groups was based on the dog
owners' final decisions for their dogs to receive or not receive rectally
administered LEV, and thus the lack of randomization is another study
limitation. The decision to perform post hoc analysis only on the
patients affected by CS was based on the few cases of SE enrolled in
both study groups. However, the results obtained for this specific
patient category were as promising as those obtained for both condi-
tions, confirming the potentially beneficial effect of rectally adminis-
tered LEV in addition to a standard treatment protocol.
Several patients were already being treated for long-term seizures
with PB and potassium bromide. Unfortunately, information on serum
concentrations of AEMs was not available or up-to-date for all
patients included, and for this reason it was not taken into account in
the final analysis of the study results. It is therefore impossible to
evaluate the influence of these medications on patient outcome.
It has been hypothesized that dogs with structural epilepsy have a
higher risk of death and presumably less control of seizure activity
despite treatment with AEMs.17-19 We found no statistically signifi-
cant difference in response rate between dogs affected with idio-
pathic epilepsy (Tier I or II confidence level of the IVETF consensus
report) and those with presumptive or confirmed structural epilepsy.
However, the final diagnosis of structural epilepsy could not be
established in all patients and, for this reason, the conclusions must be
considered with caution.
In conclusion, based on our study data, rectally administered LEV
combined with a standard treatment protocol seems to provide good
control of seizure activity in patients with CS. Because of the low
number of cases of SE included in our study, this assumption cannot
be extended to SE, and further investigations are warranted.
The validity of our results should be confirmed in a double-blinded
placebo-controlled clinical trial.
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